VRDN: Viridian Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-08-20 | New 13G stake | Point72 Asset Management, L.P. | 5.00% | SEC | |
| 2026-08-14 | 13G amendment | Paradigm BioCapital Advisors LP | 6.10% | SEC | |
| 2026-08-14 | 13G amendment | Kynam Capital Management, LP | 5.70% | SEC | |
| 2026-08-14 | New 13G stake | T. Rowe Price Associates, Inc. | 5.20% | SEC | |
| 2026-08-14 | Fell below 5% | Deep Track Capital, LP | 3.25% | SEC | |
| 2026-08-07 | New 13G stake | STATE STREET CORPORATION | 5.50% | SEC |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.